¼¼°èÀÇ Ç×ü ¾à¹° Á¢ÇÕü ¼öŹ Á¦Á¶ ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м®(¸µÄ¿º°, Áõ»óº°, Áö¿ªº°), ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Linker (Cleavable, Non-cleavable), By Condition (Myeloma, Lymphoma, Breast Cancer), By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1678517
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ç×ü ¾à¹° Á¢ÇÕü ¼öŹ Á¦Á¶ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è Ç×ü ¾à¹° Á¢ÇÕü ¼öŹ Á¦Á¶ ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2030³â¿¡ °ÉÃÄ 10.99%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. 2030³â±îÁö 165¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾÷°èÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î´Â ¼öŹ Á¦Á¶ ¼ö¿ä¿¡ ±â¿©ÇÏ´Â Ç×ü ¾à¹° º¹ÇÕü(ADC)ÀÇ º¹ÀâÇÑ ¼ºÁú, Ç×ü Ä¡·á¿¡ °üÇÑ ¿¬±¸ Áõ°¡, ¾Ï ÀÌȯÀ²ÀÇ »ó½Â µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. À¯Çà ±â°£ µ¿¾È ¾ÏÀÇ ÀÓ»ó½ÃÇèÀº ´Ü±â°£ ÁߴܵǾú½À´Ï´Ù. ±×·¯³ª Áúº´ÀÇ ½É°¢¼ºÀ¸·Î ÀÎÇØ ÀÓ»ó½ÃÇèÀÌ ´Ù½Ã ½ÃÀ۵Ǿú½À´Ï´Ù. IQVIA Oncology Trends Report 2022¿¡ µû¸£¸é ¾ÏÀÇ ÀÓ»ó½ÃÇè ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

IQVIAÀÇ º¸°í¼­¿¡ µû¸£¸é 2016³â°ú 2021³â »çÀÌ Á¾¾çÇÐÀÇ ÀÓ»ó½ÃÇèÀº 56% Áõ°¡Çß½À´Ï´Ù. ÀÌ ÀÓ»ó½ÃÇè ¼ö´Â ¼¼°è ¾ÏÀÇ À¯º´·ü Áõ°¡·Î ´õ¿í Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ADCÀÇ °³¹ß°ú Á¦Á¶ Ȱµ¿À» Áö¿øÇϰí À¯Çà ÈÄ »ê¾÷ÀÇ ¼ºÀåÀ» Áö¿øÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. Ç×ü ¾à¹° º¹ÇÕü´Â ¾Ï¼¼Æ÷¸¸À» Ç¥ÀûÀ¸·Î Çϰí, ü³»ÀÇ °Ç°­ÇÑ ¼¼Æ÷¿¡´Â ¿µÇâÀ» ÁÖÁö ¾Ê±â ¶§¹®¿¡ ¾ÏÀÇ Ä¡·á¿¡ À־ ³ôÀº È¿À²À» ¹ßÈÖÇÕ´Ï´Ù. ±× °á°ú, ¿©·¯ ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷µéÀÌ ADC °ü·Ã ¿¬±¸¿¡ »ó´çÇÑ ÀÚ±Ý Áö¿øÀ» ¹Þ°í ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, 2022³â 10¿ù, ¸¶ºí¸µÅ© ¹ÙÀÌ¿À»çÀ̾𽺴 Ç×ü ¾à¹° º¹ÇÕüÀÇ ÆÄÀÌÇÁ¶óÀÎÀ» ±¸ÃàÇϱâ À§ÇØ ½Ã¸®Áî A Àڱݿ¡¼­ 3,100¸¸ ´Þ·¯¸¦ Á¶´ÞÇß½À´Ï´Ù. ÀÌ¿Í °°ÀÌ ADCÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸¹Àº ÅõÀÚ´Â ÇâÈÄ ¼ö³â°£ ADCÀÇ °¡¿ë¼ºÀ» Çâ»ó½Ã۰í ADC ¼öŹÁ¦Á¶ ¼ö¿ä¸¦ Áö¿øÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. 2021³â 9¿ù, ¹Ì±¹ FDA´Â ADC tisotumab vedotin-tftv¿¡ ´ëÇØ º´¼¼ ÁøÇà ¶Ç´Â È­Çпä¹ý ÈÄ Àç¹ß¼º ¶Ç´Â ÀüÀ̼º Àڱà °æºÎ¾Ï ¼ºÀΠȯÀÚÀÇ Ä¡·á¿¡ ´ëÇÑ Á¶±â ½ÂÀÎÀ» ÁÖ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÂÀÎÀº ÇâÈÄ ¼ö³â°£ ADC ¼öŹ Á¦Á¶ ¼­ºñ½º ¼ö¿ä¸¦ ³ôÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç×ü ¾à¹° Á¢ÇÕü ¼öŹ Á¦Á¶ ½ÃÀå : ºÐ¼® °³¿ä

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Ç×ü ¾à¹° Á¢ÇÕü ¼öŹ Á¦Á¶ ½ÃÀå : º¯µ¿ ¿äÀÎ, °æÇâ, ¹üÀ§

Á¦4Àå Ç×ü ¾à¹° Á¢ÇÕü ¼öŹ Á¦Á¶ ½ÃÀå : Áõ»óº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦5Àå Ç×ü ¾à¹° Á¢ÇÕü ¼öŹ Á¦Á¶ ½ÃÀå :¸µÄ¿º° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦6Àå Ç×ü ¾à¹° Á¢ÇÕü ¼öŹ Á¦Á¶ ½ÃÀå : Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦7Àå °æÀï ±¸µµ

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Antibody Drug Conjugates Contract Manufacturing Market Growth & Trends:

The global antibody drug conjugates contract manufacturing market size is expected to reach USD 16.55 billion by 2030, registering a CAGR of 10.99% from 2025 to 2030, according to a new report by Grand View Research, Inc. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing to the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing to the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.

The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected to rise even further owing to the growing prevalence of cancer worldwide. This is expected to support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.

For instance, in October 2022, Mablink Bioscience, raise USD 31 million from Series A funding to build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected to improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected to boost the demand for contract manufacturing services for ADC.

Antibody Drug Conjugates Contract Manufacturing Market Report Highlights:

Table of Contents

Chapter 1. Research Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Variables, Trends & Scope

Chapter 4. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Condition Estimates & Trend Analysis

Chapter 5. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Linker Estimates & Trend Analysis

Chapter 6. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Regional Estimates & Trend Analysis

Chapter 7. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â